KPV (Lysine–Proline–Valine) is a bioactive tripeptide fragment derived from the alpha-melanocyte stimulating hormone (α-MSH) pathway. Research suggests KPV may interact with inflammatory and immune-signaling pathways involved in cytokine regulation, tissue repair, and cellular inflammatory responses.

Unlike broader melanocortin peptides, KPV is primarily researched for its targeted anti-inflammatory and immune-modulating activity while demonstrating minimal melanocyte-stimulating effects in experimental settings.

Research models have explored KPV’s potential influence on:

• Cytokine and inflammatory-signaling modulation
• Gut-barrier and intestinal-integrity support
• Tissue-repair and recovery pathways
• Skin-health and redness-related research
• Immune-system regulation
• Oxidative-stress and inflammatory-response pathways

KPV is commonly investigated in gastrointestinal and inflammatory research because of its potential interaction with pathways associated with:

• TNF-α (tumor necrosis factor alpha)
• NF-κB inflammatory signaling
• Cytokine-response regulation
• Cellular inflammatory stress responses

Research also explores KPV in skin and recovery-focused models involving irritation, redness, inflammatory stress, and tissue recovery physiology.

Due to its relatively small peptide structure and targeted inflammatory-pathway research profile, KPV is frequently studied in combination with other recovery and regenerative peptides in broader inflammation-support research models.

For research use only.

Inflammation & Immune-System Research

KPV is widely researched for its potential interaction with inflammatory and immune-signaling pathways. Studies investigate its role in cytokine modulation, inflammatory-response regulation, oxidative-stress pathways, and immune-system balance in chronic inflammatory research models.

Gastrointestinal & Gut-Health Research

KPV is commonly investigated in gastrointestinal and intestinal-barrier research involving:

• Gut-integrity support
• Intestinal inflammatory pathways
• Microbiome-related signaling
• Epithelial-tissue recovery
• Inflammatory bowel research models

Skin-Health & Dermatological Research

KPV is frequently studied in dermatological research focused on:

• Psoriasis-related inflammatory pathways
• Eczema and dermatitis research
• Redness and irritation modulation
• Skin-barrier support
• Tissue-repair and recovery signaling

Tissue-Repair & Recovery Research

Research models explore KPV’s potential role in:

• Cellular repair pathways
• Recovery physiology
• Inflammation-related tissue stress
• Regenerative and recovery-focused peptide research

Cytokine & Cellular-Signaling Research

KPV is commonly researched for its potential interaction with:

• TNF-α signaling
• NF-κB inflammatory pathways
• Cytokine-response regulation
• Oxidative-stress pathways
• Cellular inflammatory signaling

Microbiome & Barrier-Function Research

Emerging research also investigates KPV’s potential influence on:

• Gut-barrier integrity
• Skin-barrier support
• Microbiome-related inflammatory balance
• Epithelial recovery pathways

Combination Peptide Research

KPV is often researched alongside peptides such as:

• BPC-157
• TB-500
• GHK-Cu

These combinations are investigated for complementary roles in inflammation modulation, tissue repair, regenerative signaling, and skin-health research.

For research use only.

Synergistic Effect

KPV is frequently researched alongside complementary peptides and regenerative compounds due to its targeted anti-inflammatory and immune-modulating research profile. In research settings, synergistic combinations are explored for their potential effects on inflammation regulation, tissue repair, gut integrity, skin health, and recovery physiology.

With BPC-157

KPV is commonly researched alongside BPC-157 in gastrointestinal and tissue-repair models. While KPV is investigated for inflammatory-pathway modulation and immune signaling, BPC-157 is often researched for tissue-repair and recovery pathways. Research models explore whether the combination may provide complementary support for gut integrity, inflammatory balance, and epithelial recovery.

With TB-500

KPV is also studied alongside TB-500 in regenerative and recovery-focused research. Experimental models investigate potential synergistic effects involving inflammation modulation, tissue recovery, cellular migration pathways, and recovery from inflammatory or physical stress.

With GHK-Cu

In skin and regenerative research models, KPV is frequently combined with GHK-Cu. Researchers explore complementary roles involving:

• Skin-barrier support
• Redness and irritation modulation
• Collagen-related pathways
• Tissue-repair signaling
• Recovery-focused skin research

With Gut & Microbiome Research Protocols

Because KPV is commonly investigated in gut-health and inflammatory research, it is often studied alongside compounds involved in:

• Gut-barrier support
• Microbiome regulation
• Epithelial integrity
• Cytokine-response modulation

Researchers investigate whether these combinations may support broader gastrointestinal and inflammatory research objectives.

With Anti-Inflammatory Research Compounds

KPV is frequently researched in broader inflammation-focused protocols due to its potential interaction with cytokine and inflammatory-signaling pathways such as TNF-α and NF-κB. Combination protocols are often explored for complementary inflammatory-response modulation and recovery support.

Selective Inflammatory-Pathway Research

Unlike some broader melanocortin compounds, KPV is researched for its relatively targeted inflammatory and immune-signaling profile while demonstrating minimal melanocyte-stimulating activity in experimental models.

For research use only.

Compound Name:

KPV (Lysine–Proline–Valine)

Chemical Classification:

Synthetic Tripeptide Fragment of Alpha-Melanocyte Stimulating Hormone (α-MSH)

Composition:

KPV is a bioactive tripeptide composed of the following amino acids:

• L-Lysine
• L-Proline
• L-Valine

KPV represents the C-terminal tripeptide fragment of the naturally occurring alpha-melanocyte stimulating hormone (α-MSH) peptide and is researched for its targeted anti-inflammatory and immune-modulating signaling properties.

Molecular Formula:

C₁₆H₃₀N₄O₅

Appearance:

White to off-white lyophilised powder

Solubility:

Water soluble

Research Category:

Inflammation-modulating and immune-signaling research peptide

Common Research Areas:

• Inflammation and cytokine-signaling research
• Gut-health and intestinal-barrier studies
• Psoriasis and eczema-related research
• Skin-health and redness-modulation studies
• Tissue-repair and regenerative research
• Microbiome and epithelial-integrity investigations

Stability:

Typically supplied in lyophilised form to support peptide stability, purity, and long-term storage integrity during laboratory handling and research use.

For research purposes only.

KPV (30mg) — Research Dosage Guidance

Inflammation Research • Gut Support • Skin-Health Research • Recovery Support

Reconstitution (Mixing)

• Add 3ml bacteriostatic water to the vial
• Inject slowly down the side of the vial
• Allow peptide to dissolve naturally
• Swirl gently if needed
• Do not shake
• Store reconstituted peptide in the refrigerator (2–8°C)

Concentration Calculation

$30\text{ mg}÷3\text{ ml}=10\text{ mg/ml}$

• Every 10 insulin units (0.1ml) = 1mg
• Every 1 insulin unit = 100mcg

Standard Research Dosage Guidelines

Typical Research Protocols

1. Gut-Health & Intestinal Research

(Gut integrity and inflammatory-pathway models)

• Dose: 250–500mcg
• Frequency: 1–2× daily
• Duration: 6–12 weeks

Research Notes

Frequently investigated for gut-barrier support, inflammatory signaling, and epithelial recovery pathways.

2. Skin-Health & Dermatological Research

(Psoriasis, eczema, redness, and irritation research)

• Dose: 250–500mcg
• Frequency: Once daily
• Duration: 6–10 weeks

Research Notes

Commonly researched for inflammatory skin pathways, redness modulation, and skin-barrier support.

3. Inflammation & Immune-Modulation Research

(Cytokine and inflammatory-response models)

• Dose: 500mcg–1mg
• Frequency: 1–2× daily
• Duration: 6–12 weeks

Research Notes

Investigated for potential interaction with TNF-α, NF-κB, and cytokine-related signaling pathways.

4. Recovery & Tissue-Repair Research

(Regenerative and recovery-focused models)

• Dose: 500mcg–1mg
• Frequency: Once daily
• Duration: 4–8 weeks

Research Notes

Often researched alongside BPC-157 and TB-500 in tissue-repair and recovery-focused protocols.

Approximate Vial Duration

Important Research Notes

• Rotate injection sites regularly
• Use sterile needles and alcohol swabs
• Do not reuse or share needles
• Store reconstituted peptide refrigerated at 2–8°C
• Protect from excessive heat and direct sunlight
• Do not shake after mixing

Commonly Investigated Research Areas

• Inflammation and cytokine signaling
• Gut-health and intestinal-barrier research
• Psoriasis and eczema-related pathways
• Skin-health and redness-modulation studies
• Tissue repair and regenerative signaling
• Immune-system and microbiome research

For research use only.

Possible Side Effects (Observed in Research & Clinical Settings)

KPV is generally regarded in research settings as a well-tolerated peptide with a targeted inflammatory-pathway research profile. Observed responses are typically mild and may vary depending on dosage, protocol duration, administration method, and individual sensitivity.

Commonly Reported Research Observations

• Mild injection-site redness or irritation
• Temporary itching or small localized welts
• Mild nausea
• Temporary fatigue or drowsiness
• Headaches
• Light-headedness
• Mild digestive discomfort

Gastrointestinal & Immune-Response Considerations

Because KPV is frequently researched in gut-health and inflammatory models, some research settings may observe:

• Temporary digestive changes
• Mild abdominal discomfort
• Temporary shifts in inflammatory-response signaling

Skin & Inflammatory Research Considerations

In dermatological and inflammatory-pathway research, temporary responses may include:

• Mild redness or flushing
• Temporary skin sensitivity
• Mild irritation during early protocol stages

Injection & Handling Considerations

Improper storage, mixing, or administration techniques may increase the risk of:

• Injection-site irritation
• Local inflammation
• Reduced peptide stability or effectiveness

Additional Research Notes

• KPV is commonly researched for its relatively targeted anti-inflammatory and immune-modulating activity.
• Higher dosages do not necessarily produce proportionally greater effects and may increase the likelihood of side effects.
• Individual responses may vary depending on inflammatory status and overall sensitivity.

For research use only.

KPV (Lysine–Proline–Valine) is a bioactive tripeptide fragment derived from the alpha-melanocyte stimulating hormone (α-MSH) pathway and is widely researched for its potential anti-inflammatory and immune-modulating activity. It is commonly investigated in research involving gut health, inflammatory signaling, skin-health pathways, tissue repair, and immune-system regulation.

Unlike broader melanocortin peptides, KPV is researched for its relatively selective inflammatory-pathway activity with minimal melanocyte-stimulating effects observed in experimental settings. Research models frequently explore its potential interaction with cytokine signaling, gut-barrier integrity, skin irritation pathways, and recovery-focused regenerative processes.

Observed side effects in research settings are generally mild and may include temporary injection-site irritation, mild digestive discomfort, headaches, or temporary fatigue depending on dosage, protocol duration, and individual sensitivity.

Proper reconstitution, sterile handling practices, slow administration, and regular injection-site rotation are important for maintaining peptide stability and minimizing local irritation during research use.

For research use only.